Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NINTOC-TU
2024-517005-85-00Phase 3Completed
- Sponsor
- National Institute of Geriatrics, Rheumatology and Rehabilitation
- Start
- Oct 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of nintedanib and tocilizumab in pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD) (2 arms), sponsored by National Institute of Geriatrics, Rheumatology and Rehabilitation. Primary endpoint: Change in forced vital capacity (FVC) in mL at week 56. Started Oct 2024; status: completed.
02
Drugs
nintedanibtocilizumab
03
Conditions
pulmonary fibrosis secondary to systemic sclerosis (SSc-ILD)
Beyond the preview
Go deeper on 2024-517005-85-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517005-85-00.